Patients
OUR MISSION
Oncofibro advances innovative advanced therapies through a global translational and clinical development pathway. Our human program is focused on areas of high unmet medical need, beginning with advanced non–small cell lung cancer (NSCLC), while our veterinary formulation enables treatment options for pets facing severe cancers and difficult-to-treat infections.
HUMAN USE
Focus on Non‑Small Cell Lung Cancer (NSCLC)
Lung cancer remains one of the most common and lethal cancers worldwide. In Singapore, it is among the most frequently diagnosed cancers and carries one of the highest mortality rates, particularly in men, underscoring the urgent need for improved therapeutic options in advanced disease.
Our initial focus is on advanced NSCLC, guided by:
- Early clinical experience in real-world compassionate use settings.
-
Substantial unmet clinical need, particularly among patients who:
- Are diagnosed at advanced or metastatic stages.
- Lack actionable driver mutations, leaving them with limited targeted therapy options.
- Carry mutations for which no approved targeted therapy currently exist, including KRAS non‑G12C variants.
- Have progressed despite chemotherapy, immunotherapy, or available targeted treatments.
- Exhausted standard of care including other medical interventions such as surgery and/or nuclear medicine.
These patients represent a significant proportion of the NSCLC population. In later lines of therapy, physicians often face limited options and actively seek additional strategies to support disease control and quality of life.
Access & Reimbursement Strategy
Innovative therapies must be both clinically meaningful and
economically accessible. At Oncofibro, access planning begins early
in development — not after approval. In Singapore* and other
advanced healthcare systems, certain Cell, Tissue and Gene Therapy
Products (CTGTPs) may qualify for structured reimbursement and
government subsidy frameworks, subject to regulatory and clinical
evaluation. We design our programs with these pathways in mind,
considering clinical positioning, health economics, and real-world
integration from the outset.
Our strategy includes:
- Early engagement with clinical stakeholders to define meaningful outcomes
- Alignment with national regulatory and subsidy frameworks
- Integration of biomarker strategies to support appropriate patient selection
- Collaboration with payers and institutional partners to anticipate reimbursement considerations
- Manufacturing approaches that prioritize scalability and cost-efficiency
VETERINARY USE
In parallel with our human program, our veterinary formulation, Treactivus™, is designed to support pets diagnosed with:
- Severe or advanced cancers
- Intractable or treatment‑resistant infections
